medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 2

<< Back Next >>

Ann Hepatol 2017; 16 (2)

Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism

Saeedi R, Mojebi-Mogharar A, Sandhu SK, Dubland JA, Ford Jo-Ann, Yousefi M, Pudek M, Holmes DT, Erb SR, Peter KWC, Kendler DlL, Yoshida EM

Language: English
References: 19
Page: 207-214
PDF size: 152.23 Kb.


ABSTRACT

Background. Patients with chronic hepatitis B virus (HBV) are often treated with nucleoside/nucleotide antiviral agents and metabolic bone toxicity is a possible concern. Objective. To determine the relationships between fibroblast growth factor 23 (FGF23), a phosphaturic hormone, bone mineral density (BMD), and bone biochemical abnormalities in these patients. Material and methods. This is a cross-sectional observational study comparing HBV-infected subjects treated for at least one year with tenofovir (TDF), lamuvidine (LVD), entacavir (ETV), or not treated (CON). Patients with abnormalities in either calcium (Ca), phosphate (PO4), intact parathyroid hormone (iPTH) or FGF23 were further evaluated with BMD by DXA. Results. No difference in liver enzymes or renal function seen among groups, but hypophosphatemia was seen in all groups with the highest incidence with TDF-treatment (14%). FGF 23 levels were found to be elevated in 11.1% of TDF patients, 2.77% amongst controls. No elevations were found in the LVD or ETV groups. Among a subset of subjects (FGF23, PO4, and/or Ca abnormalities) who underwent further evaluation, 67% had insufficient 25-OH vitamin D, and 30% had elevated 24 h urinary Ca or PO4 excretion. No patients with FGF23 abnormalities had urine abnormalities. 40% had low DXA Z-score (‹-2) at spine or hip but there was no difference between control and antiviral treatment groups and the mean FRAX score was 2.33% for major osteoporotic fractures and 0.29% for hip fracture. Conclusion. Abnormalities in bone metabolism, particularly involving vitamin D insufficiency, in HBV-treated subjects were observed with a small increased likelihood in TDF treated patients.


REFERENCES

  1. Gua R, Lui HF. Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol 2011; 91: 8017.

  2. Köklü S, Tuna Y, Gülsen MT, Demir M, Köksal AS, Koçkar MC, Aygün C, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis b virus-related cirrhosis. Clin Gastroenterol Hepatol 2013; 11: 88-94.

  3. Wong V, Chan H. Chronic hepatitis B: A treatment update. Semin Liver Dis 2013; 33: 122-9.

  4. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open label follow-up study. Lancet 2013; 381: 468-75.

  5. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49:S185-S195.

  6. Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA, Kallis YN, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis 2015; 211: 374-82.

  7. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011; 57: 773-80.

  8. Saeedi R, Jiang SY, Holmes DT, Kendler DL. Fibroblast Growth Factor 23 is Elevated in Tenofovir-Related Hypophosphatemia. Calcified Tissue International 2014; 94: 665- 8.

  9. Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, Ghany MG, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012; 35: 1317-25.

  10. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus the tenofoviremtricitabine in HIV-infected adults: 48 week results from the ASSERT study. Clin Infect Dis 2010; 51: 963-72.

  11. Wanner DP, Tyndall A, Walker UA. Tenofovir-induced osteomalacia. Clin Exp Rheumatol 2009; 27: 1001-3.

  12. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, Mansky KC. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun 2010; 394: 48-53.

  13. Ramon I, Kleynen P, Body JJ, Karmali R. Fibroblast growth factor 23 and its role in phosphate homeostasis. Eur J Endocrinol 2010; 162: 1-10.

  14. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphonate homeostasis. J Bone Miner Res 2004; 19: 429-35.

  15. Tourret J, Deray G, Isnard-Bagnis C. Assessment of the feasibility of using sunlight exposure to obtain the recommended level of vitamin D in Canada. CMAJ Open 2015; 3: E258-E63.

  16. Shimizu Y, Hiraoka A, Yamago H, Shiraishi A, Imai Y, Tatsukawa H, Tanihira T, et al. Hypophosphatemia in patients with hepatitis B virus infection undergoing long-term adefovir dipivoxil therapy. Hepatol Res 2014; 44: 1081-7.

  17. Girgis CM, Wong T, Ngu MC, Emmett L, Archer KA, Chen RC, Seibel MJ. Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. J Clin Gastroenterol 2011; 45: 468-73.

  18. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Mansky KC. Tenofovir-associated bone density loss. Ther Clin Risk Manag 2010; 2(6): 41-7.

  19. Lane NE, Parimi N, Corr M, Yao W, Cauley JA, Nielson CM, Ix JH, et al. Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res 2013; 28: 2325-32.




2020     |     www.medigraphic.com